Skip to main content

Table 3 Haplotype of CpG sites between CAD patients and controls (%)

From: A preliminary study showing no association between methylation levels of C3 gene promoter and the risk of CAD

Haplotype Depth CAD (%) Control (%) P
CCCC 79,034 49.2 ± 5.9 47.8 ± 7.2 0.135
TTTT 60,288 34.2 ± 6.6 35.4 ± 7.6 0.179
TCCC 5947 3.6 ± 1.2 3.8 ± 2.3 0.671
TTCT 4449 2.5 ± 0.8 2.6 ± 0.8 0.358
CTCC 4221 2.7 ± 0.9 2.6 ± 0.9 0.283
CCCT 3688 2.3 ± 1.0 2.2 ± 0.7 0.890
CCTC 3666 2.3 ± 0.7 2.3 ± 0.7 0.772
  1. CAD coronary artery disease